Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces the appointment of Lorenzo Gallon, MD, as Chair of the Company’s Science Advisory Board (SAB). Dr. Gallon was appointed to the Company’s Board as a Non-executive Director on 19 August 2021.
A Professor of Medicine (Nephrology and Hypertension) and Surgery (Organ Transplantation), Dr. Gallon is currently the Medical Director of the Translational Medicine Programme, the Director of International Relations and the Director of the Renal Transplant Fellowship at Northwestern University. He is an alumnus of the University of Padua Medical School, Italy and Harvard Medical School.
An expert in nephrology and hypertension as well as organ transplantation, Dr. Gallon’s primary research interests include:
With nearly 20 years’ experience in the life sciences industry, focusing largely on nephrology and organ transplantation, Dr. Gallon is excellently placed to provide insight and guidance in the development of Verici’s two lead products, Clarava™ and Tuteva™. He was a collaborator and co-author with Verici’s previous SAB Chair, Dr. Barbara Murphy, in the GoCar study1 which was foundational in the development of Verici’s products. He has also been a member of the Editorial Board at the journal Nephron since 2019.
In 2012, Dr Gallon was part the Northwestern Medicine transplant team that conducted the first successful removal and implantation of a kidney from one patient to another after the organ failed in the first recipient. The findings of the case were published in the New England Journal of Medicine.
Julian Baines, MBE, Non-executive Chairman of Verici Dx, said:
“I am delighted to welcome Lorenzo as the new Chair of Verici Dx’s Science Advisory Board. As a leading expert in nephrology and organ transplantation, he has been hugely valuable on the Board so far, and I’m sure will become even more so in this additional role, helping us accelerate development of our two lead products, Clarava™ and Tuteva™.”
Dr Lorenzo Gallon, Non-executive Director of Verici Dx, said:
“I am pleased to take on this additional role with Verici Dx, as Chair of the Science Advisory Board. I have been impressed with the progress of its product portfolio, which has the potential to really improve outcomes for kidney transplant patients, and look forward to working more closely with the team to provide advice and some experience to help advance the products.”
1 - https://pubmed.ncbi.nlm.nih.gov/27452608/
Sara Barrington, CEO
Julian Baines, Chairman
www.vericidx.com
Via Walbrook PR
N+1 Singer (Nominated Adviser & Broker)
Aubrey Powell / Kailey Aliyar / Tom Salvesen
Tel: 020 7496 3000
Walbrook PR Limited
Paul McManus / Sam Allen
Tel: 020 7933 8780 or vericidx@walbrookpr.com
Mob: 07980 541 893 / 07748 651 727
